Skip to main content
. Author manuscript; available in PMC: 2013 Jan 3.
Published in final edited form as: Breast Cancer Res Treat. 2012 Jul 1;134(3):1279–1290. doi: 10.1007/s10549-012-2129-y

Table 3.

Independent associations of moderate-to-vigorous activity and sedentary time with breast cancer odds, by timing of treatment1

Timing of Monitor Wear in Relation to Treatment (No. of cases)

Average minutes
per day*
Controls
(N=1,164)
Cases Monitor worn
prior to surgery
& other
treatments
(N=141)
Cases Monitor worn
after surgery but
prior to other
treatments
(N=230)
Cases Monitor worn
after surgery
& other
treatments
(N=381)
Cases Surgery date
unknown
(N=118)
Cases Treatment date
unknown
(N=105)
Moderate-to-
vigorous, min/day
 ≤ 65.0 292 47 1.00 135 1.00 155 1.00 49 1.00 55 1.00
 65.10 - 95.58 290 38 0.72 (0.44, 1.17) 50 0.41 (0.27, 0.60) 113 0.83 (0.60, 1.16) 29 0.62 (0.37, 1.06) 24 0.54 (0.31, 0.95)
 95.59 - 128.24 291 31 0.56 (0.32, 0.98) 24 0.22 (0.13, 0.37) 70 0.56 (0.37, 0.83) 19 0.44 (0.23, 0.83) 13 0.37 (0.18, 0.77)
 ≥ 128.25 291 24 0.43 (0.22, 0.86) 21 0.25 (0.13, 0.47) 43 0.42 (0.25, 0.70) 21 0.55 (0.26, 1.17) 13 0.49 (0.21, 1.17)


Sedentary, min/day
 ≤ 396.60 291 24 1.00 24 1.00 63 1.00 24 1.00 15 1.00
 396.61 - 457.74 291 41 1.37 (0.78, 2.42) 50 1.52 (0.86, 2.68) 86 1.22 (0.82, 1.84) 26 1.07 (0.56, 2.02) 21 1.38 (0.64, 2.94)
 457.75 - 524.10 291 43 1.30 (0.70, 2.39) 65 1.85 (1.02, 3.34) 96 1.36 (0.88, 2.12) 35 1.41 (0.72, 2.75) 31 1.95 (0.88, 4.31)
 ≥ 524.11 291 33 0.78 (0.37, 1.63) 91 2.40 (1.26, 4.57) 136 2.25 (1.37, 3.70) 33 1.37 (0.63, 3.00) 38 2.52 (1.05, 6.07)
*

Time spent sedentary or in moderate-to-vigorous activity calculated as the average minutes per day across valid days of wear. Categories determined by the quartile distribution among controls; behavior defined by the following counts: sedentary (0-99 counts) and moderate-to-vigorous (760+ counts); data for moderate-to-vigorous activity missing for one case.

1

Models adjusted for the following: age, BMI, and wear time. Cases who wore the monitor prior to surgery and after other treatments were excluded from these analyses (n=21) due to small numbers across accelerometer categories.